Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on October 26, 2022, to report its financial results for the third quarter of 2022. The filing primarily references a press release issued on October 25, 2022, which contains the detailed financial performance for the quarter. Investors should refer to this press release and accompanying supplemental information for specific figures regarding revenue, earnings, and other key financial metrics. Additionally, the report includes a presentation made on October 26, 2022, which discusses financial and operating initiatives. This presentation, along with the earnings press release and supplemental information, should be reviewed together to gain a comprehensive understanding of the company's recent performance and strategic direction. Notably, the company utilizes non-GAAP financial information, and reconciliations to GAAP measures are provided in the supplemental materials.
Key Highlights
- 1BMY reported its third quarter 2022 financial results via an earnings press release on October 25, 2022.
- 2The 8-K filing includes the earnings press release (Exhibit 99.1) and supplemental financial information (Exhibit 99.2).
- 3A presentation on financial and operating initiatives, dated October 26, 2022 (Exhibit 99.3), was also made available.
- 4Investors are directed to review the earnings press release and supplemental information for detailed Q3 2022 financial performance.
- 5The company's presentation includes references to non-GAAP financial information.
- 6Reconciliations between non-GAAP and GAAP financial measures are provided in the supplemental information.
- 7The filing does not contain new operational updates beyond the Q3 earnings announcement and related presentation.